Pilot study of combination 5-fluorouracil, cisdiamminedichloroplatinum II, and radiation therapy for grade III and IV astrocytomas
Nineteen patients with biopsy-proven high-grade astrocytomas received as initial treatment whole-brain radiation and combination chemotherapy with 5-fluorouracil (5-FU), 1000 mg/m/sup 2//24 h as a continuous infusion for 96 h, and bolus cisdiamminedichloroplatinum II (CDDP), 100 mg/m/sup 2/. Chemotherapy cycles were repeated on day 21, then every 28 days until progression or completion of six cycles. All 19 patients completed one cycle of chemotherapy. Toxicity was moderate, with cytopenias, nausea, vomiting, diarrhea, stomatitis, and reversible azotemia. Survival ranged from 2 to 160+ weeks, with a median of 35 weeks. The survival of the pilot group was compared with historical controls treated with radiation plus 1,3,-bis(2-chloroethyl)-1-nitrosourea (BCNU). Controls were similar in histology, age, performance score, and survival, without statistically significant differences. The combination of radiation therapy, continuous-infusion 5-FU, and bolus CDDP as described here for high-grade astrocytomas is moderately toxic and appears to offer no survival advantage compared with radiation therapy plus BCNU.
- Research Organization:
- Harper-Grace Hospital, Detroit, MI
- OSTI ID:
- 5849640
- Journal Information:
- Am. J. Clin. Oncol.; (United States), Journal Name: Am. J. Clin. Oncol.; (United States) Vol. 10:5; ISSN AJCOD
- Country of Publication:
- United States
- Language:
- English
Similar Records
Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus
Misonidazole and radiotherapy to treat malignant glioma: a Phase II trial of the radiation therapy oncology group
Related Subjects
550603* -- Medicine-- External Radiation in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIMETABOLITES
ANTINEOPLASTIC DRUGS
ASTROCYTOMAS
AZINES
BODY
BRAIN
CENTRAL NERVOUS SYSTEM
COMBINED THERAPY
DISEASES
DRUGS
FLUOROURACILS
GLIOMAS
HETEROCYCLIC COMPOUNDS
HYDROXY COMPOUNDS
NEOPLASMS
NERVOUS SYSTEM
ORGANIC COMPOUNDS
ORGANIC FLUORINE COMPOUNDS
ORGANIC HALOGEN COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PATIENTS
PYRIMIDINES
RADIOSENSITIVITY EFFECTS
RADIOSENSITIZERS
SURVIVAL CURVES
THERAPY
TOXICITY
URACILS